Published in BMC Biochem on February 03, 2011
Structural and functional similarity of amphibian constitutive androstane receptor with mammalian pregnane X receptor. PLoS One (2014) 1.39
Vitamin D: calcium and bone homeostasis during evolution. Bonekey Rep (2014) 0.98
Action of vitamin D and the receptor, VDRa, in calcium handling in zebrafish (Danio rerio). PLoS One (2012) 0.94
Functional characterization of a full length pregnane X receptor, expression in vivo, and identification of PXR alleles, in zebrafish (Danio rerio). Aquat Toxicol (2013) 0.80
Role of pregnane X receptor and aryl hydrocarbon receptor in transcriptional regulation of pxr, CYP2, and CYP3 genes in developing zebrafish. Toxicol Sci (2014) 0.78
Marine invertebrate xenobiotic-activated nuclear receptors: their application as sensor elements in high-throughput bioassays for marine bioactive compounds. Mar Drugs (2014) 0.77
Functional diversification of vitamin D receptor paralogs in teleost fish after a whole genome duplication event. Endocrinology (2014) 0.77
Cytochrome P450 20A1 in zebrafish: Cloning, regulation and potential involvement in hyperactivity disorders. Toxicol Appl Pharmacol (2016) 0.76
Lxr regulates lipid metabolic and visual perception pathways during zebrafish development. Mol Cell Endocrinol (2015) 0.76
Evolutionary Origin of the Interferon-Immune Metabolic Axis: The Sterol-Vitamin D Link. Front Immunol (2017) 0.75
Evolutionary and Functional Diversification of the Vitamin D Receptor-Lithocholic Acid Partnership. PLoS One (2016) 0.75
Annotation of the Nuclear Receptors in an Estuarine Fish species, Fundulus heteroclitus. Nucl Receptor Res (2017) 0.75
Development and validation of a genetic algorithm for flexible docking. J Mol Biol (1997) 14.36
Genome duplication in the teleost fish Tetraodon nigroviridis reveals the early vertebrate proto-karyotype. Nature (2004) 11.03
Identification of a nuclear receptor for bile acids. Science (1999) 7.81
Bile acids: natural ligands for an orphan nuclear receptor. Science (1999) 7.18
Anatomy of protein pockets and cavities: measurement of binding site geometry and implications for ligand design. Protein Sci (1998) 7.03
The enzymes, regulation, and genetics of bile acid synthesis. Annu Rev Biochem (2003) 6.35
Vitamin effects on the immune system: vitamins A and D take centre stage. Nat Rev Immunol (2008) 5.37
Vitamin D. Am J Physiol Renal Physiol (2005) 4.81
Endogenous bile acids are ligands for the nuclear receptor FXR/BAR. Mol Cell (1999) 4.76
Vitamin D receptor as an intestinal bile acid sensor. Science (2002) 3.64
The human nuclear xenobiotic receptor PXR: structural determinants of directed promiscuity. Science (2001) 3.27
Orphan nuclear receptors constitutive androstane receptor and pregnane X receptor share xenobiotic and steroid ligands. J Biol Chem (2000) 3.23
LXRS and FXR: the yin and yang of cholesterol and fat metabolism. Annu Rev Physiol (2006) 3.11
A chemical, genetic, and structural analysis of the nuclear bile acid receptor FXR. Mol Cell (2003) 2.85
The crystal structure of the nuclear receptor for vitamin D bound to its natural ligand. Mol Cell (2000) 2.77
Bile acids: chemistry, pathochemistry, biology, pathobiology, and therapeutics. Cell Mol Life Sci (2008) 2.60
Bile salt evolution. J Lipid Res (1967) 1.79
Structural overview of the nuclear receptor superfamily: insights into physiology and therapeutics. Annu Rev Physiol (2010) 1.68
Transcriptional control of intestinal cytochrome P-4503A by 1alpha,25-dihydroxy vitamin D3. Mol Pharmacol (2001) 1.67
Pregnane X receptor (PXR), constitutive androstane receptor (CAR), and benzoate X receptor (BXR) define three pharmacologically distinct classes of nuclear receptors. Mol Endocrinol (2002) 1.67
Disrupted bile acid homeostasis reveals an unexpected interaction among nuclear hormone receptors, transporters, and cytochrome P450. J Biol Chem (2001) 1.67
Regulation of a xenobiotic sulfonation cascade by nuclear pregnane X receptor (PXR). Proc Natl Acad Sci U S A (2002) 1.65
Detoxification of lithocholic acid, a toxic bile acid: relevance to drug hepatotoxicity. Drug Metab Rev (2004) 1.64
Coactivator binding promotes the specific interaction between ligand and the pregnane X receptor. J Mol Biol (2003) 1.57
Structural disorder in the complex of human pregnane X receptor and the macrolide antibiotic rifampicin. Mol Endocrinol (2005) 1.55
2.1 A crystal structure of human PXR in complex with the St. John's wort compound hyperforin. Biochemistry (2003) 1.55
T0901317 is a potent PXR ligand: implications for the biology ascribed to LXR. FEBS Lett (2007) 1.54
Unexpected novel relational links uncovered by extensive developmental profiling of nuclear receptor expression. PLoS Genet (2007) 1.52
High pressure liquid chromatographic analysis of conjugated bile acids in human bile: simultaneous resolution of sulfated and unsulfated lithocholyl amidates and the common conjugated bile acids. J Lipid Res (1987) 1.51
T0901317 is a dual LXR/FXR agonist. Mol Genet Metab (2004) 1.50
Enzymes in the conversion of cholesterol into bile acids. Curr Mol Med (2007) 1.46
Binding of ligands and activation of transcription by nuclear receptors. Annu Rev Biophys Biomol Struct (2001) 1.46
Evolution and function of vitamin D. Recent Results Cancer Res (2003) 1.43
Structural basis for bile acid binding and activation of the nuclear receptor FXR. Mol Cell (2003) 1.40
Regulation of xenobiotic and bile acid metabolism by the nuclear pregnane X receptor. J Lipid Res (2002) 1.39
How bile acids confer gut mucosal protection against bacteria. Proc Natl Acad Sci U S A (2006) 1.38
Bile salts of vertebrates: structural variation and possible evolutionary significance. J Lipid Res (2009) 1.37
Evolution of the pregnane x receptor: adaptation to cross-species differences in biliary bile salts. Mol Endocrinol (2005) 1.33
Evolution and function of the NR1I nuclear hormone receptor subfamily (VDR, PXR, and CAR) with respect to metabolism of xenobiotics and endogenous compounds. Curr Drug Metab (2006) 1.32
Crystal structure of the pregnane X receptor-estradiol complex provides insights into endobiotic recognition. Mol Endocrinol (2007) 1.25
Identification of farnesoid X receptor beta as a novel mammalian nuclear receptor sensing lanosterol. Mol Cell Biol (2003) 1.25
The first completed genome sequence from a teleost fish (Fugu rubripes) adds significant diversity to the nuclear receptor superfamily. Nucleic Acids Res (2003) 1.20
Crystal structure of the PXR-T1317 complex provides a scaffold to examine the potential for receptor antagonism. Bioorg Med Chem (2006) 1.19
Functional evolution of the vitamin D and pregnane X receptors. BMC Evol Biol (2007) 1.17
Evolutionary selection across the nuclear hormone receptor superfamily with a focus on the NR1I subfamily (vitamin D, pregnane X, and constitutive androstane receptors). Nucl Recept (2005) 1.17
Evolution of pharmacologic specificity in the pregnane X receptor. BMC Evol Biol (2008) 1.14
BXR, an embryonic orphan nuclear receptor activated by a novel class of endogenous benzoate metabolites. Genes Dev (1998) 1.10
Nuclear receptors: one big family. Methods Mol Biol (2009) 1.10
Novel inhibitors of human organic cation/carnitine transporter (hOCTN2) via computational modeling and in vitro testing. Pharm Res (2009) 1.09
A phylogenetic survey of biliary lipids in vertebrates. J Lipid Res (2005) 1.08
Evolution of the bile salt nuclear receptor FXR in vertebrates. J Lipid Res (2008) 1.08
Adaptability of the Vitamin D nuclear receptor to the synthetic ligand Gemini: remodelling the LBP with one side chain rotation. J Steroid Biochem Mol Biol (2007) 1.06
Ligand specificity and evolution of liver X receptors. J Steroid Biochem Mol Biol (2008) 1.06
Diversity of bile salts in fish and amphibians: evolution of a complex biochemical pathway. Physiol Biochem Zool (2010) 1.04
The nuclear xenobiotic receptor pregnane X receptor: recent insights and new challenges. Mol Endocrinol (2005) 1.04
The farnesoid X receptor FXRalpha/NR1H4 acquired ligand specificity for bile salts late in vertebrate evolution. Am J Physiol Regul Integr Comp Physiol (2007) 1.03
A pharmacophore for human pregnane X receptor ligands. Drug Metab Dispos (2002) 1.03
Challenges predicting ligand-receptor interactions of promiscuous proteins: the nuclear receptor PXR. PLoS Comput Biol (2009) 1.01
Physicochemical and physiological properties of 5alpha-cyprinol sulfate, the toxic bile salt of cyprinid fish. J Lipid Res (2003) 0.99
Selective activation of vitamin D receptor by lithocholic acid acetate, a bile acid derivative. J Lipid Res (2004) 0.99
PXR and the regulation of apoA1 and HDL-cholesterol in rodents. Pharmacol Res (2004) 0.98
Evolution of promiscuous nuclear hormone receptors: LXR, FXR, VDR, PXR, and CAR. Mol Cell Endocrinol (2010) 0.97
Functional evolution of the pregnane X receptor. Expert Opin Drug Metab Toxicol (2006) 0.96
Natural occurrence and chemical synthesis of bile alcohols, higher bile acids, and short side chain bile acids. Hiroshima J Med Sci (1994) 0.96
Structural investigation of the ligand binding domain of the zebrafish VDR in complexes with 1alpha,25(OH)2D3 and Gemini: purification, crystallization and preliminary X-ray diffraction analysis. J Steroid Biochem Mol Biol (2004) 0.94
Intestinal cell-specific vitamin D receptor (VDR)-mediated transcriptional regulation of CYP3A4 gene. Biochem Pharmacol (2009) 0.93
FOR, a novel orphan nuclear receptor related to farnesoid X receptor. J Biol Chem (2002) 0.93
Paralogous vitamin D receptors in teleosts: transition of nuclear receptor function. Endocrinology (2008) 0.92
Structural determinants for vitamin D receptor response to endocrine and xenobiotic signals. Mol Endocrinol (2003) 0.91
Role of vitamin D receptor in the lithocholic acid-mediated CYP3A induction in vitro and in vivo. Drug Metab Dispos (2008) 0.90
The identification of ligand features essential for PXR activation by pharmacophore modeling. J Chem Inf Model (2005) 0.90
Evolutionary diversity of bile salts in reptiles and mammals, including analysis of ancient human and extinct giant ground sloth coprolites. BMC Evol Biol (2010) 0.87
Functional and structural characterization of the insertion region in the ligand binding domain of the vitamin D nuclear receptor. Eur J Biochem (2001) 0.87
Vitamin D and the skin. J Dermatol (2003) 0.84
Exposure to the synthetic FXR agonist GW4064 causes alterations in gene expression and sublethal hepatotoxicity in eleutheroembryo medaka (Oryzias latipes). Toxicol Appl Pharmacol (2009) 0.82
Two farnesoid X receptor alpha isoforms in Japanese medaka (Oryzias latipes) are differentially activated in vitro. Aquat Toxicol (2010) 0.81
1alpha,25-Dihydroxyvitamin D(3) triggered vitamin D receptor and farnesoid X receptor-like effects in rat intestine and liver in vivo. Biopharm Drug Dispos (2009) 0.81
Major biliary bile acids of the medaka (Oryzias latipes): 25R- and 25S-epimers of 3alpha,7alpha,12alpha-trihydroxy-5beta-cholestanoic acid. Zoolog Sci (2010) 0.79
COMPLEX EVOLUTION OF BILE SALTS IN BIRDS. Auk (2010) 0.77
Tea polyphenol (-)-epigallocatechin-3-gallate inhibits DNA methyltransferase and reactivates methylation-silenced genes in cancer cell lines. Cancer Res (2003) 3.72
Bisphenol A and its analogues activate human pregnane X receptor. Environ Health Perspect (2012) 1.81
Lack of androgenicity and estrogenicity of the three monomers used in Eastman's Tritan™ copolyesters. Food Chem Toxicol (2012) 1.76
A novel method for generation of signature networks as biomarkers from complex high throughput data. Toxicol Lett (2005) 1.71
Rapid identification of P-glycoprotein substrates and inhibitors. Drug Metab Dispos (2006) 1.68
Oral bile acids reduce bacterial overgrowth, bacterial translocation, and endotoxemia in cirrhotic rats. Hepatology (2003) 1.51
Novel web-based tools combining chemistry informatics, biology and social networks for drug discovery. Drug Discov Today (2009) 1.40
Human pregnane X receptor antagonists and agonists define molecular requirements for different binding sites. Mol Pharmacol (2007) 1.39
Towards a gold standard: regarding quality in public domain chemistry databases and approaches to improving the situation. Drug Discov Today (2012) 1.39
Design, synthesis, cytoselective toxicity, structure-activity relationships, and pharmacophore of thiazolidinone derivatives targeting drug-resistant lung cancer cells. J Med Chem (2008) 1.37
Bile salts of vertebrates: structural variation and possible evolutionary significance. J Lipid Res (2009) 1.37
Human cecal bile acids: concentration and spectrum. Am J Physiol Gastrointest Liver Physiol (2007) 1.35
Evolution of the pregnane x receptor: adaptation to cross-species differences in biliary bile salts. Mol Endocrinol (2005) 1.33
Computational models for drug inhibition of the human apical sodium-dependent bile acid transporter. Mol Pharm (2009) 1.26
Mobile apps for chemistry in the world of drug discovery. Drug Discov Today (2011) 1.26
Mouse organic solute transporter alpha deficiency enhances renal excretion of bile acids and attenuates cholestasis. Hepatology (2010) 1.26
Methods for predicting human drug metabolism. Adv Clin Chem (2007) 1.24
A quality alert and call for improved curation of public chemistry databases. Drug Discov Today (2011) 1.22
Altered bile acid metabolism in childhood functional constipation: inactivation of secretory bile acids by sulfation in a subset of patients. J Pediatr Gastroenterol Nutr (2008) 1.21
Molecular determinants of substrate/inhibitor binding to the human and rabbit renal organic cation transporters hOCT2 and rbOCT2. Mol Pharmacol (2005) 1.21
New predictive models for blood-brain barrier permeability of drug-like molecules. Pharm Res (2008) 1.20
Notch1 co-opts lymphoid enhancer factor 1 for survival of murine T-cell lymphomas. Blood (2007) 1.18
The importance of discerning shape in molecular pharmacology. Trends Pharmacol Sci (2009) 1.17
Functional evolution of the vitamin D and pregnane X receptors. BMC Evol Biol (2007) 1.17
Evolutionary selection across the nuclear hormone receptor superfamily with a focus on the NR1I subfamily (vitamin D, pregnane X, and constitutive androstane receptors). Nucl Recept (2005) 1.17
A generalizable pre-clinical research approach for orphan disease therapy. Orphanet J Rare Dis (2012) 1.16
Pharmacophore-based discovery of ligands for drug transporters. Adv Drug Deliv Rev (2006) 1.15
Evolution of pharmacologic specificity in the pregnane X receptor. BMC Evol Biol (2008) 1.14
Reaching out to collaborators: crowdsourcing for pharmaceutical research. Pharm Res (2010) 1.14
A comprehensive in vitro and in silico analysis of antibiotics that activate pregnane X receptor and induce CYP3A4 in liver and intestine. Drug Metab Dispos (2008) 1.14
Bacterial peptide recognition and immune activation facilitated by human peptide transporter PEPT2. Am J Respir Cell Mol Biol (2008) 1.13
Using molecular similarity to highlight the challenges of routine immunoassay-based drug of abuse/toxicology screening in emergency medicine. BMC Emerg Med (2009) 1.12
A "forward genomics" approach links genotype to phenotype using independent phenotypic losses among related species. Cell Rep (2012) 1.10
Novel inhibitors of human organic cation/carnitine transporter (hOCTN2) via computational modeling and in vitro testing. Pharm Res (2009) 1.09
Elucidating the 'Jekyll and Hyde' nature of PXR: the case for discovering antagonists or allosteric antagonists. Pharm Res (2009) 1.09
Accurate enzymatic measurement of fecal bile acids in patients with malabsorption. J Lab Clin Med (2003) 1.09
Evolving carbapenemases: can medicinal chemists advance one step ahead of the coming storm? J Med Chem (2010) 1.09
Influence of molecular structure on substrate binding to the human organic cation transporter, hOCT1. Mol Pharmacol (2003) 1.08
A phylogenetic survey of biliary lipids in vertebrates. J Lipid Res (2005) 1.08
Evolution of the bile salt nuclear receptor FXR in vertebrates. J Lipid Res (2008) 1.08
Molecular determinants of ligand selectivity for the human multidrug and toxin extruder proteins MATE1 and MATE2-K. J Pharmacol Exp Ther (2012) 1.07
Multifaceted roles of ultra-rare and rare disease patients/parents in drug discovery. Drug Discov Today (2013) 1.07
Ligand specificity and evolution of liver X receptors. J Steroid Biochem Mol Biol (2008) 1.06
Detection of Δ4-3-oxo-steroid 5β-reductase deficiency by LC-ESI-MS/MS measurement of urinary bile acids. J Chromatogr B Analyt Technol Biomed Life Sci (2012) 1.05
Challenges and recommendations for obtaining chemical structures of industry-provided repurposing candidates. Drug Discov Today (2012) 1.05
Chemical target and pathway toxicity mechanisms defined in primary human cell systems. J Pharmacol Toxicol Methods (2009) 1.04
Essential metabolites of Mycobacterium tuberculosis and their mimics. MBio (2011) 1.04
Using open source computational tools for predicting human metabolic stability and additional absorption, distribution, metabolism, excretion, and toxicity properties. Drug Metab Dispos (2010) 1.04
Inhibition of human liver catechol-O-methyltransferase by tea catechins and their metabolites: structure-activity relationship and molecular-modeling studies. Biochem Pharmacol (2005) 1.04
Time for cooperation in health economics among the modelling community. Pharmacoeconomics (2010) 1.04
Shape signatures: new descriptors for predicting cardiotoxicity in silico. Chem Res Toxicol (2008) 1.01
Challenges predicting ligand-receptor interactions of promiscuous proteins: the nuclear receptor PXR. PLoS Comput Biol (2009) 1.01
Comparative pharmacophore modeling of organic anion transporting polypeptides: a meta-analysis of rat Oatp1a1 and human OATP1B1. J Pharmacol Exp Ther (2005) 1.01
Structure-activity relationship for FDA approved drugs as inhibitors of the human sodium taurocholate cotransporting polypeptide (NTCP). Mol Pharm (2013) 0.99
Machine learning methods and docking for predicting human pregnane X receptor activation. Chem Res Toxicol (2008) 0.99
Bile acid-induced secretion in polarized monolayers of T84 colonic epithelial cells: Structure-activity relationships. Am J Physiol Gastrointest Liver Physiol (2006) 0.99
Computational discovery of novel low micromolar human pregnane X receptor antagonists. Mol Pharmacol (2008) 0.98
An in vivo look at vertebrate liver architecture: three-dimensional reconstructions from medaka (Oryzias latipes). Anat Rec (Hoboken) (2007) 0.98
PXR and the regulation of apoA1 and HDL-cholesterol in rodents. Pharmacol Res (2004) 0.98
Evolution of promiscuous nuclear hormone receptors: LXR, FXR, VDR, PXR, and CAR. Mol Cell Endocrinol (2010) 0.97
Parallel worlds of public and commercial bioactive chemistry data. J Med Chem (2014) 0.97
Structural biology and function of solute transporters: implications for identifying and designing substrates. Drug Metab Rev (2002) 0.97
Computational approaches that predict metabolic intermediate complex formation with CYP3A4 (+b5). Drug Metab Dispos (2007) 0.96
Functional evolution of the pregnane X receptor. Expert Opin Drug Metab Toxicol (2006) 0.96
Redefining Cheminformatics with Intuitive Collaborative Mobile Apps. Mol Inform (2012) 0.96
Comprehensive computational assessment of ADME properties using mapping techniques. Curr Drug Discov Technol (2005) 0.95
Computational models to assign biopharmaceutics drug disposition classification from molecular structure. Pharm Res (2007) 0.94
Combining cheminformatics methods and pathway analysis to identify molecules with whole-cell activity against Mycobacterium tuberculosis. Pharm Res (2012) 0.94
Novel yeast-based strategy unveils antagonist binding regions on the nuclear xenobiotic receptor PXR. J Biol Chem (2013) 0.93
Discovery of novel antimalarial compounds enabled by QSAR-based virtual screening. J Chem Inf Model (2013) 0.93
Resolving mechanisms of toxicity while pursuing ecotoxicological relevance? Mar Pollut Bull (2005) 0.93
Integrated in silico-in vitro strategy for addressing cytochrome P450 3A4 time-dependent inhibition. Chem Res Toxicol (2010) 0.93
Identification and validation of novel human pregnane X receptor activators among prescribed drugs via ligand-based virtual screening. Drug Metab Dispos (2010) 0.92
Paralogous vitamin D receptors in teleosts: transition of nuclear receptor function. Endocrinology (2008) 0.92
Intrinsic disorder in nuclear hormone receptors. J Proteome Res (2008) 0.92
Nuclear factor-E2-related factor 2 is a major determinant of bile acid homeostasis in the liver and intestine. Am J Physiol Gastrointest Liver Physiol (2012) 0.91
Optimizing higher throughput methods to assess drug-drug interactions for CYP1A2, CYP2C9, CYP2C19, CYP2D6, rCYP2D6, and CYP3A4 in vitro using a single point IC(50). J Biomol Screen (2002) 0.91
Novel biotransformation and physiological properties of norursodeoxycholic acid in humans. Hepatology (2005) 0.91
Pharmacophore modeling of cytochromes P450. Adv Drug Deliv Rev (2002) 0.90
2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD) induces organ- specific differential gene expression in male Japanese medaka (Oryzias latipes). Toxicol Sci (2005) 0.90
Quantitative structure activity relationship for inhibition of human organic cation/carnitine transporter. Mol Pharm (2010) 0.90
Effects of antipsychotic drugs on I(to), I (Na), I (sus), I (K1), and hERG: QT prolongation, structure activity relationship, and network analysis. Pharm Res (2006) 0.90
Reengineering the pharmaceutical industry by crash-testing molecules. Drug Discov Today (2005) 0.90
Potent inhibitors of human organic anion transporters 1 and 3 from clinical drug libraries: discovery and molecular characterization. Mol Pharm (2012) 0.89
Computational models for neglected diseases: gaps and opportunities. Pharm Res (2013) 0.89
Troubleshooting computational methods in drug discovery. J Pharmacol Toxicol Methods (2010) 0.89
The omega-6 fatty acid linoleic acid is associated with risk of gastroschisis: a novel dietary risk factor. Am J Med Genet A (2012) 0.89
Identification of previously unrecognized antiestrogenic chemicals using a novel virtual screening approach. Chem Res Toxicol (2006) 0.89
Kohonen maps for prediction of binding to human cytochrome P450 3A4. Drug Metab Dispos (2004) 0.88
Hybrid scoring and classification approaches to predict human pregnane X receptor activators. Pharm Res (2008) 0.88
TCDD induced pericardial edema and relative COX-2 expression in medaka (Oryzias Latipes) embryos. Toxicol Sci (2010) 0.87